PL BioScience, a German life sciences company specialising in the production and development of human platelet lysate (HPL) for cell expansion, has announced the strengthening of its management team with the appointment of Oliver Dick as chief technology officer. This intends to support HPL upscaling in alignment with growing global demand for its animal-free cell […]
The post PL BioScience appoints Oliver Dick as chief technology officer appeared first on Pharmafile.
